• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Thursday's After-Market Session

    11/30/23 4:31:04 PM ET
    $AKAN
    $ALT
    $AMPE
    $BIAF
    Medicinal Chemicals and Botanical Products
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AKAN alert in real time by email

    Gainers

    • Altimmune (NASDAQ:ALT) shares increased by 45.2% to $4.59 during Thursday's after-market session. The company's market cap stands at $246.6 million.
    • NovaBay Pharmaceuticals (AMEX:NBY) stock increased by 9.89% to $0.33. The market value of their outstanding shares is at $2.1 million.
    • China Pharma Holding (AMEX:CPHI) shares rose 9.63% to $0.12. The market value of their outstanding shares is at $3.9 million.
    • NeuBase Therapeutics (NASDAQ:NBSE) stock moved upwards by 9.48% to $1.08. The company's market cap stands at $4.0 million.
    • Minerva Surgical (NASDAQ:UTRS) stock increased by 8.1% to $2.0. The market value of their outstanding shares is at $17.7 million.
    • Akanda (NASDAQ:AKAN) stock increased by 7.95% to $0.53. The company's market cap stands at $2.0 million.

    Losers

    • Ampio Pharmaceuticals (AMEX:AMPE) shares declined by 20.5% to $4.58 during Thursday's after-market session. The market value of their outstanding shares is at $3.8 million.
    • Corbus Pharmaceuticals (NASDAQ:CRBP) stock declined by 9.23% to $6.0. The company's market cap stands at $26.5 million.
    • Eagle Pharmaceuticals (NASDAQ:EGRX) shares decreased by 8.55% to $5.35. The company's market cap stands at $69.4 million.
    • bioAffinity Technologies (NASDAQ:BIAF) stock declined by 8.49% to $1.51. The market value of their outstanding shares is at $14.3 million.
    • Quoin Pharmaceuticals (NASDAQ:QNRX) stock decreased by 8.34% to $4.63. The market value of their outstanding shares is at $4.5 million.
    • LumiraDx (NASDAQ:LMDX) shares declined by 8.12% to $0.16. The company's market cap stands at $50.5 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $AKAN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AKAN
    $ALT
    $AMPE
    $BIAF

    CompanyDatePrice TargetRatingAnalyst
    Altimmune Inc.
    $ALT
    1/28/2026$20.00Overweight
    Barclays
    Corbus Pharmaceuticals Holdings Inc.
    $CRBP
    7/30/2025$28.00Buy
    B. Riley Securities
    Altimmune Inc.
    $ALT
    7/10/2025$1.00Sell
    Goldman
    Corbus Pharmaceuticals Holdings Inc.
    $CRBP
    2/28/2025Outperform
    William Blair
    Altimmune Inc.
    $ALT
    2/28/2025Mkt Perform
    William Blair
    Altimmune Inc.
    $ALT
    1/8/2025$18.00Buy
    Stifel
    Corbus Pharmaceuticals Holdings Inc.
    $CRBP
    12/2/2024Overweight
    Piper Sandler
    Altimmune Inc.
    $ALT
    11/12/2024$26.00Buy
    UBS
    More analyst ratings

    $AKAN
    $ALT
    $AMPE
    $BIAF
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Weaver Gregory L bought $17,700 worth of shares (5,000 units at $3.54), increasing direct ownership by 22% to 28,078 units (SEC Form 4)

    4 - Altimmune, Inc. (0001326190) (Issuer)

    3/9/26 7:05:04 AM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President and CEO Durso Jerome Benedict bought $70,790 worth of shares (20,000 units at $3.54), increasing direct ownership by 160% to 32,500 units (SEC Form 4)

    4 - Altimmune, Inc. (0001326190) (Issuer)

    3/9/26 7:00:05 AM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Hrt Financial Lp bought $40,650 worth of Class A Shares (29,036 units at $1.40) and sold $10,150 worth of Class A Shares (7,868 units at $1.29) (SEC Form 4)

    4 - AKANDA CORP. (0001888014) (Issuer)

    1/20/26 2:07:19 PM ET
    $AKAN
    Medicinal Chemicals and Botanical Products
    Health Care

    $AKAN
    $ALT
    $AMPE
    $BIAF
    SEC Filings

    View All

    bioAffinity Technologies Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - bioAffinity Technologies, Inc. (0001712762) (Filer)

    3/10/26 8:45:14 AM ET
    $BIAF
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form 10-K filed by Corbus Pharmaceuticals Holdings Inc.

    10-K - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Filer)

    3/9/26 4:16:00 PM ET
    $CRBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Corbus Pharmaceuticals Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Filer)

    3/9/26 7:43:03 AM ET
    $CRBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKAN
    $ALT
    $AMPE
    $BIAF
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Barclays initiated coverage on Altimmune with a new price target

    Barclays initiated coverage of Altimmune with a rating of Overweight and set a new price target of $20.00

    1/28/26 7:15:18 AM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    B. Riley Securities resumed coverage on Corbus Pharma with a new price target

    B. Riley Securities resumed coverage of Corbus Pharma with a rating of Buy and set a new price target of $28.00

    7/30/25 8:22:15 AM ET
    $CRBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Goldman resumed coverage on Altimmune with a new price target

    Goldman resumed coverage of Altimmune with a rating of Sell and set a new price target of $1.00

    7/10/25 8:47:17 AM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKAN
    $ALT
    $AMPE
    $BIAF
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Weaver Gregory L bought $17,700 worth of shares (5,000 units at $3.54), increasing direct ownership by 22% to 28,078 units (SEC Form 4)

    4 - Altimmune, Inc. (0001326190) (Issuer)

    3/9/26 7:05:04 AM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President and CEO Durso Jerome Benedict bought $70,790 worth of shares (20,000 units at $3.54), increasing direct ownership by 160% to 32,500 units (SEC Form 4)

    4 - Altimmune, Inc. (0001326190) (Issuer)

    3/9/26 7:00:05 AM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Medical Officer Smethurst Dominic sold $50,601 worth of shares (6,097 units at $8.30), decreasing direct ownership by 6% to 89,790 units (SEC Form 4)

    4 - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Issuer)

    3/4/26 4:30:18 PM ET
    $CRBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKAN
    $ALT
    $AMPE
    $BIAF
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    bioAffinity Technologies Announces Initiation of Large-Scale Longitudinal Clinical Study for Its Noninvasive CyPath® Lung Cancer Diagnostic

    Study to evaluate clinical performance of CyPath® Lung for the early detection of lung cancer in high-risk patients Murtha Cancer Center Research Program at Uniformed Services University of the Health Sciences provides support for longitudinal study bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)), a biotechnology company focused on non-invasive diagnostics and early cancer detection, today announced initiation of the Company's planned large-scale, longitudinal clinical study for CyPath® Lung, its noninvasive diagnostic test for the detection of early-stage lung cancer. The 2,000-patient longitudinal study is designed to evaluate the clinical performance of the CyPath® Lung flow c

    3/10/26 7:47:00 AM ET
    $BIAF
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Altimmune Announces Fourth Quarter and Full-year 2025 Financial Results and Business Updates

    Initiation of Phase 3 MASH trial planned for 2026 Pemvidutide granted FDA Breakthrough Therapy Designation in MASH Topline data from RECLAIM Phase 2 trial of pemvidutide in alcohol use disorder (AUD) expected in third quarter 2026 Cash, cash equivalents and short-term investments of $274 million as of December 31, 2025; Balance sheet further strengthened through $75 million registered direct offering in January 2026 Webcast to be held today, March 5, 2026, at 8:30 a.m. ET GAITHERSBURG, Md., March 05, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced financial

    3/5/26 7:00:00 AM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    bioAffinity Technologies Presents Positive Research Findings for its Novel Diagnostic Platform Technology to Identify Optimal Therapies for Asthma Patients

    Poster presented to medical and drug industry conferees at prestigious American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting Research demonstrates the technology's ability to identify drug antibody receptors in sputum for two leading asthma therapies bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)), a biotechnology company focused on noninvasive diagnostics and early cancer detection, today announced the presentation of a new scientific poster reporting on the ability of the Company's innovative diagnostic approach to identify antibody drug receptors in sputum, including receptors for dupilumab, a leading therapy for asthma and chronic obstructive pulmonary disease

    3/3/26 8:30:00 AM ET
    $BIAF
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $AKAN
    $ALT
    $AMPE
    $BIAF
    Leadership Updates

    Live Leadership Updates

    View All

    bioAffinity Technologies Appoints Nationally Recognized Pulmonary and Lung Cancer Authorities to its Medical and Scientific Advisory Board

    Advisory Board provides independent guidance on strategic priorities, including growing adoption of the Company's noninvasive CyPath® Lung diagnostic test bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)), a biotechnology company focused on noninvasive diagnostics and early cancer detection, today announced new appointments to its Medical and Scientific Advisory Board, welcoming David Ost, MD, MPH, University of Texas MD Anderson Cancer Center, Daniel Sterman, MD, New York University Langone Medical Center, and J. Scott Ferguson, MD, University of Wisconsin School of Medicine and Public Health, to its panel of recognized leaders in the field. The appointments reflect a planned expans

    2/9/26 8:00:00 AM ET
    $BIAF
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Altimmune Announces CEO Transition and Succession Plan

    Jerry Durso, accomplished industry leader, to succeed Vipin Garg, Ph.D. as Chief Executive Officer Transition follows seven years of strong leadership by Dr. Garg GAITHERSBURG, Md., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and metabolic diseases, today announced a CEO succession plan under which Vipin Garg, Ph.D. will step down as the Company's President and Chief Executive Officer effective January 1, 2026. Altimmune's Chairman of the Board, Jerry Durso, will assume the role of President and Chief Executive Officer and retain his position as Chairman. To facilitat

    12/1/25 7:30:00 AM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Eagle Pharmaceuticals Announces Results of 2025 Annual Meeting of Stockholders

    WOODCLIFF LAKE, N.J., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (OTC:EGRX) (the "Company" or "Eagle") is pleased to announce the voting results for each of the matters presented at the Company's 2025 annual meeting of stockholders (the "Annual Meeting") held virtually on Friday, October 17, 2025. Of the 13,157,754 shares outstanding as of the record date, 10,769,820 shares, or approximately 82%, were present or represented by proxy at the Annual Meeting. Set forth below are the results of the matters submitted for a vote of stockholders at the Annual Meeting. 1.   Election of Directors Election of (i) two Class I nominees for director, Michael Graves and Richard Edlin

    10/21/25 4:05:00 PM ET
    $EGRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKAN
    $ALT
    $AMPE
    $BIAF
    Financials

    Live finance-specific insights

    View All

    Altimmune to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 5, 2026

    GAITHERSBURG, Md., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced that it will report its fourth quarter 2025 financial results on Thursday, March 5, 2026. Altimmune management will host a conference call at 8:30 a.m. ET on March 5 to discuss the financial results and provide a business update. The conference call will be webcast live on Altimmune's Investor Relations website at https://ir.altimmune.com/investors. Participants who would like to join the call may register here to receive dial-in numbers and a unique PIN. A replay will be available on t

    2/26/26 7:30:00 AM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Altimmune Announces that Pemvidutide Achieved Key Measures of Success at 48 Weeks in IMPACT Phase 2b MASH Trial

    Improvements observed in key non-invasive markers of fibrosis across treatment arms versus placebo, with continued reductions from 24-week timepoint Additional weight loss from 24 to 48 weeks with 1.8 mg dose, without plateauing Favorable tolerability profile of pemvidutide preserved at 48 weeks, reinforced by low treatment-related discontinuation rate End-of-Phase 2 meeting with FDA supports advancing to registrational Phase 3 trial in MASH patients with moderate to advanced liver fibrosis Conference call to be held today at 8:00 a.m. ET GAITHERSBURG, Md., Dec. 19, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a late clinical-stage biopharmaceutical company developing thera

    12/19/25 6:30:00 AM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Corbus Pharmaceuticals Reports Results from Phase 1a Study of Oral CB1 Inverse Agonist CRB-913 for the Treatment for Obesity Demonstrating Favorable Safety Profile and Emerging Evidence of Weight Loss

    CRB-913 was safe and well-tolerated across all doses studiedDaily neuropsychiatric assessments using CSSRS, PHQ-9, and GAD-7 were negative for all participantsA placebo-adjusted mean weight loss of 2.9% was observed at Day 14 in a dedicated cohort of people with obesity (n=12)A 12-week dose-finding study in people with obesity initiated with completion expected in summer 2026Company to host conference call and live webcast today at 8:00 am ET NORWOOD, Mass., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP), a clinical-stage company focused on oncology and obesity, today announced the completion of the single ascending dose (SAD) and multiple ascending d

    12/11/25 7:00:00 AM ET
    $CRBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKAN
    $ALT
    $AMPE
    $BIAF
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Corbus Pharmaceuticals Holdings Inc.

    SC 13G/A - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Subject)

    11/14/24 7:48:14 PM ET
    $CRBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Quoin Pharmaceuticals Ltd.

    SC 13G/A - Quoin Pharmaceuticals, Ltd. (0001671502) (Subject)

    11/14/24 7:23:29 PM ET
    $QNRX
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Corbus Pharmaceuticals Holdings Inc.

    SC 13G - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Subject)

    11/14/24 6:41:20 PM ET
    $CRBP
    Biotechnology: Pharmaceutical Preparations
    Health Care